EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Perspectives on STING Agonists for Anticancer Drug Development

Dilay Kahvecioglu Cicek iD

Chemical Biology & Drug Design · 2026-07 · 108 (1)

DOI: 10.1111/cbdd.70370 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 26.07.2026. Verfasst von Dilay Kahvecioglu Cicek. Beteiligte Einrichtung: Edirne Sultan 1. Murat State Hospital, Republic of Türkiye Ministry of Health, Edirne, Türkiye. Hauptthemen laut MEDLINE: Antineoplastic Agents, Membrane Proteins, Drug Development. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cyclic GMP‐AMP (cGAS) synthase and stimulator of interferon genes signaling pathway plays a central role in bridging innate and adaptive immunity, particularly within the context of cancer. Activation begins when cytosolic double‐stranded DNA is detected, leading to the production of cyclic GMP‐AMP (cGAMP) and subsequent activation of STING. This initiates a cascade that induces the expression of type I interferons (IFN) and proinflammatory cytokines, enhancing antitumor immune responses through the stimulation of dendritic cells, cytotoxic T lymphocytes, and natural killer cells. Despite strong therapeutic potential, many currently available cyclic dinucleotide (CDN) and synthetic noncyclic dinucleotide (non‐CDN) STING agonists face critical limitations. Common issues include poor pharmacokinetics, low cellular permeability, enzymatic degradation, and inadequate systemic bioavailability. In some cases, excessive immune activation has been observed, resulting in toxicity, chronic inflammation, or immunosuppressive tumor microenvironments. Furthermore, species‐specific activity restricts the translational relevance of several compounds. These limitations highlight the need for the development of novel STING agonists with improved potency, selectivity, safety, and pharmacological profiles. This review presents a detailed analysis of molecular design approaches and structure–activity relationship (SAR) data for STING agonists, emphasizing their relevance in cancer therapy. A total of 60 synthetic compounds with diverse chemical scaffolds are examined to identify structural features linked to enhanced STING activation. These findings may support the discovery of novel STING‐targeted molecules that could improve therapeutic outcomes in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMembrane ProteinsDrug DevelopmentHumansSTING ProteinAnimalsNeoplasmscGAS-STING Signaling PathwaySignal Transduction

Stichwörter der Autor:innen

STING agonistSTING pathwaycancer immunotherapycyclic GMP‐AMP synthase (cGAS)—stimulator of interferon genes (STING) pathwaycyclic dinucleotide (CDN) agonisthuman STINGnon‐cyclic dinucleotide (non‐CDN) agonist

Substanzen

Antineoplastic AgentsMembrane ProteinsSTING ProteinSTING1 protein, human

Autor:innen und Institutionen

  • Edirne Sultan 1. Murat State Hospital, Republic of Türkiye Ministry of Health, Edirne, Türkiye.

ORCID-Profile: Dilay Kahvecioglu Cicek

Zitieren

APA

Kahvecioglu Cicek, D. (2026). Current Perspectives on STING Agonists for Anticancer Drug Development. Chemical Biology & Drug Design, 108(1). https://doi.org/10.1111/cbdd.70370

Vancouver

Kahvecioglu Cicek D. Current Perspectives on STING Agonists for Anticancer Drug Development. Chemical Biology & Drug Design. 2026;108(1). doi:10.1111/cbdd.70370

BibTeX
@article{KahveciogluCicek2026,
  author = {Kahvecioglu Cicek, Dilay},
  title = {Current Perspectives on STING Agonists for Anticancer Drug Development},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {108},
  number = {1},
  doi = {10.1111/cbdd.70370}
}
Kostenlos starten →